TrialsgrambetaRCTs are beautiful

FREEDOM

2009

Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months

In 7,868 postmenopausal women with osteoporosis, denosumab 60 mg subcutaneously every 6 months reduced new vertebral, non-vertebral and hip fractures compared with placebo.

Result

Primary endpoint: New vertebral fracture

Vertebral fracture −68 % (p<0.001); hip fracture HR 0.60 (−40 %; p=0.04); non-vertebral −20 %.

Original publication
Subtopic
Denosumab
Design
Double-blind RCT, 3 yr
Relevance
Important: one of several pillars.
Source
Cummings SR, et al. N Engl J Med. 2009;361(8):756-765.doi 10.1056/NEJMoa0809493

Discussion & critique

Effective and reversible, but the rebound multiple-vertebral-fracture phenomenon on discontinuation makes seamless sequential bisphosphonate therapy essential.

Discussed in podcasts